Nucleix Ltd.

Biotechnology ResearchCentral District, Israel51-200 Employees

Nucleix Ltd. is a biotechnology research company focused on cancer diagnostics based on liquid biopsy. Its approach uses PCR-based epigenetic markers to detect cancers at early stages and to monitor recurrence, employing a non-invasive test that supports timely treatment decisions. The flagship product, Bladder EpiCheck, has regulatory clearance in Europe for primary and recurrent bladder and upper tract urinary cancers and is FDA-cleared in the United States for bladder cancer recurrence, with commercial availability in both regions. The testing platform aims to deliver reliable results while remaining practical for physicians, their patients, and the broader healthcare system.

Nucleix operates from two sites—San Diego, California and Rehovot, Israel—reflecting an international footprint in biotech research. It positions itself in the oncology diagnostics space, offering non-invasive tools that fit into existing cancer care workflows. The company is characterized as mid-sized and maintains a global reach through its dual-location presence. In 2025, Nucleix announced participation at the AUA conference to present data on Bladder EpiCheck monitoring in non-muscle invasive bladder cancer recurrence.

Sign up for free to view info

Email Format Employee directory